User:Mr. Ibrahem/Deferiprone

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Deferiprone
Clinical data
Trade namesFerriprox
AHFS/Drugs.comMonograph
MedlinePlusa612016
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classIron chelator[2]
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only) / P[3]
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
MetabolismGlucuronidation
Elimination half-life2 to 3 hours
ExcretionKidney (75 to 90% in 24 hours)
Identifiers
  • 3-hydroxy-1,2-dimethylpyridin-4(1H)-one
Chemical and physical data
FormulaC7H9NO2
Molar mass139.154 g·mol−1
3D model (JSmol)
  • O=C\1C(\O)=C(/N(/C=C/1)C)C
  • InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3 checkY
  • Key:TZXKOCQBRNJULO-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Deferiprone, sold under the brand name Ferriprox among others, is a medication used to treat iron overload due to blood transfusions in thalassaemia major.[2][4] It is taken by mouth.[5] Evidence supports improved blood markers but not symptoms or survival.[4]

Common side effects include red-brown urine, nausea, abdominal pain, and vomiting.[2] Other side effects may include low white blood cells, infection, and prolonged QT.[2][4] Use in pregnancy may harm the baby.[4] It is an iron chelator.[2]

Deferiprone became commercially available in 1994.[6] It was initially approved in Europe and Asia.[7] It is on the World Health Organization's List of Essential Medicines as an alternative to deferasirox.[8] It is available as a generic medication.[5] This was followed by approval in the United States in 2011.[4] In the United Kingdom 100 tablets of 500 mg costs the NHS about £130.[5] In the United States this amount costs about 7,500 USD.[9]

References[edit]

  1. ^ a b "Deferiprone (Ferriprox) Use During Pregnancy". Drugs.com. 30 March 2020. Archived from the original on 26 October 2020. Retrieved 20 May 2020.
  2. ^ a b c d e f g h "Ferriprox EPAR". European Medicines Agency (EMA). Archived from the original on 14 August 2020. Retrieved 20 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ^ "Ferriprox 100 mg/ml oral solution - Summary of Product Characteristics (SmPC)". (emc). 26 November 2019. Archived from the original on 7 August 2020. Retrieved 20 May 2020.
  4. ^ a b c d e f "Deferiprone Monograph for Professionals". Drugs.com. Archived from the original on 11 June 2021. Retrieved 21 December 2021.
  5. ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1075. ISBN 978-0857114105.
  6. ^ Staff. "Cipla's History". Cipla. Archived from the original on 2015-10-27.
  7. ^ Savulescu J (February 2004). "Thalassaemia major: the murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373. PMID 14962851.
  8. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  9. ^ "Ferriprox Prices, Coupons and Patient Assistance Programs". Retrieved 22 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Deferiprone&oldid=1218349816"